CDK17: A promising drug target and biomarker for cancer treatment

Target Name: CDK17

NCBI ID: G5128

CDK17

CDK17: A promising drug target and biomarker for cancer treatment

CDK17 (Chromatin-remodeling protein 17) is a key regulator of DNA replication and repair, which plays a crucial role in the development and maintenance of normal cellular processes. CDK17 has also been implicated in the regulation of cell growth, apoptosis, and angiogenesis. As a result, targeting CDK17 has become an attractive strategy for the development of new cancer therapies. In this article, we will explore the potential of CDK17 as a drug target and biomarker for cancer treatment.

CDK17 as a drug target

CDK17 is a protein that can interact with multiple DNA replication factors, including RPA1 (Ribonucleotide polymerase alpha), which is a key enzyme in the DNA replication process. By interacting with RPA1, CDK17 can regulate the initiation of DNA replication and ensure accurate replication of genetic information. Therefore, targeting CDK17 by small molecules or antibodies can potentially inhibit DNA replication and disrupt the integrity of the genetic material.

CDK17 has also been shown to play a role in the regulation of cell apoptosis. When cells are subjected to stress or DNA damage, CDK17 can induce programmed cell death (apoptosis) to eliminate damaged or dysfunctional cells. Therefore, targeting CDK17 with drugs that induce apoptosis could be an effective strategy for cancer treatment.

CDK17 as a biomarker

CDK17 has also been used as a biomarker for cancer diagnosis and prognosis. By measuring the expression of CDK17 in cancer tissues, researchers can monitor the effectiveness of different treatments and estimate patient response to therapy. For example, some studies have shown that the expression of CDK17 is significantly increased in the brains of patients with Alzheimer's disease, which is believed to be caused by the accumulation of neurodegenerate proteins. Therefore, targeting CDK17 with drugs that can reduce neurodegeneration could be a promising strategy for the treatment of Alzheimer's disease.

In addition, CDK17 has also been used as a biomarker for evaluating the efficacy of anti-cancer drugs in clinical trials. By measuring the expression of CDK17 in cancer cells, researchers can monitor the effectiveness of different treatments and estimate patient response to therapy. This can help researchers determine which drugs are most effective and identify potential biomarkers for cancer diagnosis and prognosis.

CDK17 as a drug target and biomarker

In conclusion, CDK17 is a promising drug target and biomarker for cancer treatment. By targeting CDK17 with small molecules or antibodies, researchers can disrupt DNA replication and cell apoptosis, which can lead to the inhibition of cancer growth and the destruction of cancer cells. Additionally, CDK17 can be used as a biomarker for cancer diagnosis and prognosis, which can help researchers monitor the effectiveness of different treatments and estimate patient response to therapy. Further research is needed to fully understand the potential of CDK17 as a drug target and biomarker for cancer treatment.

Protein Name: Cyclin Dependent Kinase 17

Functions: May play a role in terminally differentiated neurons. Has a Ser/Thr-phosphorylating activity for histone H1 (By similarity)

The "CDK17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDK17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets